Charles River Laboratories acquires Distributed Bio

By The Science Advisory Board staff writers

January 4, 2021 -- Charles River Laboratories has acquired Silicon Valley-based antibody drug discovery firm Distributed Bio for $83 million in cash.

The merger combines Charles River's drug discovery and nonclinical development expertise with Distributed Bio's antibody libraries and immuno-engineering platform. The acquisition occurred on December 31, 2020, and marks the culmination of an exclusive partnership between the two companies that began in October 2018.

With the acquisition, Charles River has expanded its scientific capabilities with a large-molecule discovery platform. James Foster, chair, president, and CEO of Charles River, added that the acquisition fills a gap in the company's portfolio and enhances Charles River's ability to serve as a single-source partner for clients in early-stage research.

The purchase price included $83 million in cash and up to $21 million in contingent additional payments based on future performance. Charles River financed the proposed acquisition and fees through its existing revolving credit facility and cash.

Distributed Bio had an estimated annual revenue of approximately $15 million in 2020. The company maintains the SuperHuman antibody libraries and integrated antibody optimization technologies, which help to boost the probability of successfully delivering readily formattable antibody fragments for cell and gene therapy candidates.

Copyright © 2021

Create an Account

Already have an account? Sign in Here

To access all ScienceBoard content create a free account now:

Email Address:  

First Name:

Last Name:

Learn about ScienceBoard

Get the latest life sciences research and industry news, delivered straight to your inbox, for free.

Why subscribe?

ScienceBoard is uniquely focused on the business of research, addressing the biggest problems that the biomedical industry face. You’ll get breaking news, events coverage, and deep dives into the science that drives innovation, delivered to your inbox daily.

I have read and agree to the privacy policy and terms of service and wish to opt-in for

Email Preferences

Letter from the Editor Please send me twice-weekly roundups of all the latest life research and industry news.
SAB Announcements Please send me the latest announcements from The Science Advisory Board and their partners.
Spotlight Receive notifications about new content, services, or educational resources designed to help you sharpen your skills and grow professionally.